Clinical Study

Doxycycline For Emphysema In People Living With Hiv (The Depth Trial)

Posted Date: Feb 16, 2023

  • Investigator: Carl Fichtenbaum
  • Specialties: AIDS-HIV, Pulmonary Diseases
  • Type of Study: Drug

The prevalence of emphysema is higher in people living with HIV (PLWH) compared to controls without HIV, and progression may be accelerated. PLWH with early emphysema have increased alveolar macrophage gene expression of matrix metalloproteinase genes as well as MMP protein levels in bronchoalveolar lavage (BAL) fluid samples to an even greater extent than in HIV-negative individuals with emphysema. MMPs are therefore potential targets for intervention aimed at modifying the natural history of emphysema specifically in PLWH. We hypothesize that doxycycline, an MMP inhibitor, will reduce progression of emphysema in PLWH. This study is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial of 100 mg doxycycline BID for 72 weeks for emphysema in people living with HIV.


Individuals Age 30 Years And Older With Hiv-1 Infection Who Are Current Or Former Cigarette Smokers With Evidence Of Emphysema On High Resolution Ct (Hrct) Of The Chest.


Hiv, Emphysema, Doxycycline

For More Information:

Michelle Saemann

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.